We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) Scales a 52-Week High: What's Driving It?
Read MoreHide Full Article
On Aug 21, shares of Masimo Corporation (MASI - Free Report) reached a 52-week high of $115.68, closing the session marginally lower at $115.24. Masimo’s impressive second-quarter 2018 results contributed to the stock’s rally.
Over the past year, shares of Masimo have rallied 33% against the industry’s decline of 6.8%. The current level is also higher than the S&P 500 index’s gain of 17.2%.
The California-based developer of non-invasive monitoring systems is expected to scale new highs in the near term. The company has an average positive earnings surprise of 14.7% for the trailing four quarters.
Which way are the Estimates Treading?
The estimate revision trend for the current year is impressive as well. Over the past 90 days, the Zacks Consensus Estimate for earnings per share inched up 1.4% to $2.90. The same for revenues is pegged at $846.9 million, reflecting growth of 6.1% from the year-ago.
Buoyed by a solid second-quarter show, Masimo raised its 2018 earnings and revenue guidance.
The company expects revenues of $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at cc. The Zacks Consensus Estimate stands at $846.9 million, below the projected figure.
Product revenues are projected at $822 million, up from the previously projected $818 million. The company has retained the guidance for the Royalty and Other segment.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88. Notably, the Zacks Consensus Estimate for the same is pegged at $2.90.
Product Portfolio Solid
In the recently reported second quarter, Masimo announced the launch of UniView. Management is upbeat about the positive response by hospital executives about the potential benefits of using Root with UniView, Replica and Patient SafetyNet.
The company further announced Vital Signs Check App for Root, which aims at improving patient safety and clinician productivity.
Earlier, Masimo and Thermomedics, a PositiveID company, announced the debut and U.S. market release of TIR-1, a non-contact Bluetooth-enabled thermometer that integrates seamlessly with the Masimo Root patient monitoring and connectivity platform.
Moreover, Masimo continues to witness solid show by its flagship NomoLine Capnography, SedLine Brain Function Monitoring and O3 Regional Oximetry product lines.
Expanding Margins
In the recently reported quarter, gross profit totaled $567.7 million, up 8.6% year over year. Adjusted gross margin was 66.8%, up 70 basis points (bps).
Adjusted operating income in the quarter totaled $207.1 million, up 11.7% from a year ago. Adjusted operating margin was 24.4%, up 90 bps.
Want More from the MedTech Space?
Other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Inogen Inc. (INGN - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock carries a Zacks Rank #2.
Inogen’s long-term earnings growth rate is projected at 24.5%. The stock carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Masimo (MASI) Scales a 52-Week High: What's Driving It?
On Aug 21, shares of Masimo Corporation (MASI - Free Report) reached a 52-week high of $115.68, closing the session marginally lower at $115.24. Masimo’s impressive second-quarter 2018 results contributed to the stock’s rally.
Over the past year, shares of Masimo have rallied 33% against the industry’s decline of 6.8%. The current level is also higher than the S&P 500 index’s gain of 17.2%.
The California-based developer of non-invasive monitoring systems is expected to scale new highs in the near term. The company has an average positive earnings surprise of 14.7% for the trailing four quarters.
Which way are the Estimates Treading?
The estimate revision trend for the current year is impressive as well. Over the past 90 days, the Zacks Consensus Estimate for earnings per share inched up 1.4% to $2.90. The same for revenues is pegged at $846.9 million, reflecting growth of 6.1% from the year-ago.
Masimo Corporation Price and Consensus
Masimo Corporation Price and Consensus | Masimo Corporation Quote
The stock carries a Zacks Rank #2 (Buy).
Factors Driving Masimo
View Upbeat
Buoyed by a solid second-quarter show, Masimo raised its 2018 earnings and revenue guidance.
The company expects revenues of $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at cc. The Zacks Consensus Estimate stands at $846.9 million, below the projected figure.
Product revenues are projected at $822 million, up from the previously projected $818 million. The company has retained the guidance for the Royalty and Other segment.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88. Notably, the Zacks Consensus Estimate for the same is pegged at $2.90.
Product Portfolio Solid
In the recently reported second quarter, Masimo announced the launch of UniView. Management is upbeat about the positive response by hospital executives about the potential benefits of using Root with UniView, Replica and Patient SafetyNet.
The company further announced Vital Signs Check App for Root, which aims at improving patient safety and clinician productivity.
Earlier, Masimo and Thermomedics, a PositiveID company, announced the debut and U.S. market release of TIR-1, a non-contact Bluetooth-enabled thermometer that integrates seamlessly with the Masimo Root patient monitoring and connectivity platform.
Moreover, Masimo continues to witness solid show by its flagship NomoLine Capnography, SedLine Brain Function Monitoring and O3 Regional Oximetry product lines.
Expanding Margins
In the recently reported quarter, gross profit totaled $567.7 million, up 8.6% year over year. Adjusted gross margin was 66.8%, up 70 basis points (bps).
Adjusted operating income in the quarter totaled $207.1 million, up 11.7% from a year ago. Adjusted operating margin was 24.4%, up 90 bps.
Want More from the MedTech Space?
Other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Integer Holdings Corporation (ITGR - Free Report) and Inogen Inc. (INGN - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock carries a Zacks Rank #2.
Integer Holdings has an expected long-term earnings growth rate of 15%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen’s long-term earnings growth rate is projected at 24.5%. The stock carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>